share_log

A Preview Of Champions Oncology's Earnings

A Preview Of Champions Oncology's Earnings

《冠軍腫瘤學》收入預覽
Benzinga ·  09/10 10:51

Champions Oncology (NASDAQ:CSBR) is set to give its latest quarterly earnings report on Wednesday, 2024-09-11. Here's what investors need to know before the announcement.

Champions Oncology(納斯達克股票代碼:CSBR)定於2024-09-11星期三發佈其最新的季度收益報告。以下是投資者在宣佈之前需要了解的內容。

Analysts estimate that Champions Oncology will report an earnings per share (EPS) of $-0.03.

分析師估計,Champions Oncology將公佈的每股收益(EPS)爲-0.03美元。

The announcement from Champions Oncology is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.

Champions Oncology的宣佈備受期待,投資者正在尋求超出預期的消息以及對下一季度的有利指導。

It's worth noting for new investors that guidance can be a key determinant of stock price movements.

對於新投資者來說,值得注意的是,指導可能是股價走勢的關鍵決定因素。

Overview of Past Earnings

過去的收益概述

Last quarter the company beat EPS by $0.17, which was followed by a 2.54% increase in the share price the next day.

上個季度,該公司每股收益高出0.17美元,隨後第二天股價上漲了2.54%。

Here's a look at Champions Oncology's past performance and the resulting price change:

以下是Champions Oncology過去的表現以及由此產生的價格變化:

Quarter Q4 2024 Q3 2024 Q2 2024 Q1 2024
EPS Estimate -0.16 -0.15 -0.17 -0.10
EPS Actual 0.01 -0.16 -0.15 -0.16
Price Change % 3.0% -3.0% 5.0% -1.0%
季度 2024 年第四季度 2024 年第三季度 2024 年第二季度 2024 年第一季度
每股收益估算 -0.16 -0.15 -0.17 -0.10
實際每股收益 0.01 -0.16 -0.15 -0.16
價格變動% 3.0% -3.0% 5.0% -1.0%
1725979894_0.png

Market Performance of Champions Oncology's Stock

冠軍腫瘤學股票的市場表現

Shares of Champions Oncology were trading at $4.23 as of September 06. Over the last 52-week period, shares are down 23.09%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release.

截至9月6日,Champions Oncology的股票交易價格爲4.23美元。在過去的52週中,股價下跌了23.09%。鑑於這些回報率通常爲負數,長期股東在發佈本業績時可能會有些沮喪。

To track all earnings releases for Champions Oncology visit their earnings calendar on our site.

要追蹤Champions Oncology的所有業績,請訪問我們網站上的業績日曆。

This article was generated by Benzinga's automated content engine and reviewed by an editor.

本文由Benzinga的自動內容引擎生成,並由編輯審閱。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論